Company Focus
Bayer
Latest Bayer News
Pharmaceutical
Germany’s Bayer announced on Friday that it plans to invest $2.2 bill in a new pharmaceutical manufacturing site in New Albany, Ohio, USA, adding to the string of major drugmakers announcing multibillion-dollar US projects in recent months. 3 October 2026
Related News
Latest News & Features of interest to Bayer
Biotechnology
US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg), has appointed Greg DiPasquale as its chief commercial officer (CCO). 9 October 2026
Biotechnology
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, according to an amended S-1 filed with the SEC Thursday. 9 October 2026
Biotechnology
Privately-held Endeavor BioMedicines said its Phase IIb WHISTLE-PF trial of taladegib (ENV-101) met its primary endpoint in idiopathic pulmonary fibrosis (IPF), with a statistically significant improvement in lung function against placebo. 9 October 2026
Pharmaceutical
When the World Health Organization (WHO) updates its Model List of Essential Medicines (EML), it gives governments a reference point for deciding which treatments their health systems should prioritize. Its choices can inform public purchasing and insurance coverage, although countries make their own decisions about what to fund. 9 October 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved oche’s Tecentriq atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumor characterized by high mutation rates. 9 October 2026
Pharmaceutical
US pharma major Bristol Myers Squibb said its Phase III EXCALIBER-RRMM trial met its progression-free survival (PFS) endpoint, with Zenbexus (iberdomide) plus daratumumab and dexamethasone (ZDd) beating daratumumab, bortezomib and dexamethasone (DVd) in relapsed or refractory multiple myeloma, including patients at first relapse. 8 October 2026
Biotechnology
US biotech company MimiVax plans to discuss potential expedited regulatory pathways for its experimental cancer vaccine SurVaxM after a Phase IIb glioblastoma trial missed its primary endpoint but reported better outcomes in a prespecified group of younger patients. 8 October 2026
Biotechnology
US pharma giant Pfizer yesterday revealed that the US Food and Drug Administration (FDA) has approved Tukysa (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. 8 October 2026
Biotechnology
The US Food and Drug Administration (FDA) has granted two Breakthrough Therapy designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), from US pharma major AbbVie. 8 October 2026
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (trade name Korjuny) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible. 7 October 2026
Latest In Brief for Bayer
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze